Today: December 14, 2018, 2:33 am
  
Health

Cadrock Secures US$5m for Therapy Targeting $35 billion Heart Disease Market

Cadrock Secures US$5m for Therapy Targeting $35 billion Heart Disease Market
PR-Inside.com: 2018-09-04 04:32:31
- Enrolls first clinical trial patients in Sydney, Australia


SYDNEY, Sept 4, 2018 - (ACN Newswire) - Cadrock Pty Ltd, which owns an investigational prevention and treatment therapy for coronary artery disease (CAD), has secured a US$5 million seed investment from a Chinese investor to fund clinical trials.


Cadrock is potentially disrupting the entire heart-care sector by proposing CAD is caused by bacterial infection.


Cadrock data is backed by a clinical trial treating CAD as an infection with an antibiotic therapy in London, UK, which demonstrated a 36% reduction in Major Cardiac Events (MCEs) (STAMINA).


"Where there is inflammation, look for infection," says Professor Borody, who is well known globally for discovering the cure for the peptic ulcer bacterial infection, using a triple antibiotic therapy.


His triple antibiotic therapy for peptic ulcers prevented 18,655 premature deaths and saved the Australian Government an estimated AU$10.03 billion (THEMA Report).


Professor Borody has now developed and patented a new investigational triple antibiotic therapy to combat the infection believed to cause CAD.


"The Cadrock therapy is targeting the $35 billion CAD market and is the only therapy focused on the cause of CAD rather than suspected risk factors," said Professor Borody.


The first Cadrock interventional clinical trial of the triple therapy at Liverpool Hospital, Sydney Australia, has just enrolled its second patient.


The study is recruiting 60 people with CAD and will "evaluate the effect of antibiotic combination therapy on objective measures of improvement in coronary flow as determined by fractional flow reserve (FFR) intra-coronary imaging (Intravascular ultrasound [IVUS] and/or Optical Coherence Tomography [OCT]) in subjects undergoing percutaneous coronary intervention (PCI) with non-critical lesions in non-culprit arteries."


Professor Borody is most famous for discovering the triple antibiotic therapy for peptic ulcers in 1985, after Nobel Prize recipients Barry Marshall and Robin Warren discovered infection as the cause.


Professor Borody said, "CAD heart disease and stroke are the world's biggest killers with around 15 million deaths in 2015. In the US alone heart disease is the leading cause of death for both men and women - 610,000 people die of heart disease in the United States annually. (Source: CDC).


In China, about 230 million or 1/5 people have cardiovascular disease. (Source: Harvard University)


Additionally, peripheral vascular disease worldwide afflicts around 200 million people.


Statins form part of the first line treatment of CAD but reduce Major Cardiac Events (MCEs) in preventative studies by as little as 0.2-0.6%. (Jupiter)


About Cadrock ( www.cadrockacac.com)


Cadrock Pty Ltd has a novel investigational prevention and treatment therapy for coronary heart disease (CAD) developed by Professor Thomas Borody, who discovered the cure for peptic ulcers. The Cadrock therapy is targeting the $35 billion CAD market and is the only therapy focused on the cause of CAD, rather than suspected risk factors. The Cadrock therapy is now in clinical trials in Australia. For more information, and access to the Digify investor VDR, please contact investor relations at IR@Cadrockacac.com.

Press Information


Published by
ACN Newswire
+65 6304 8926
e-mail
www.acnnewswire.com



# 485 Words
Related Articles
More From The Author
[Legend Holdings] Revenues in Key Sectors Lift [..]
HONG KONG - (ACN Newswire) - According to South China Morning Post's report, the interim results posted by Legend Holdings [..]
NEGTEC launches Crowdfunding Portal promoting Regenerative Medicine
Dream-Kicker.com to offer donation-based, cryptocurrency support for cutting-edge regenerative medicine and medical equipment TOKYO, [..]
DOCOMO selects IOTW to develop Micro-Mining for [..]
AnApp Blockchain Technologies Ltd ( AnApp ), the IoT blockchain developer behind IOTW, a new cryptocurrency for IoT applications, is [..]
ETRI showcases Consumer Electronic Technologies of the [..]
Korea's ETRI will present some of its innovative advancements this week at Internationale Funkausstellung (IFA), the world's largest [..]
Tonghai Financial Announces 2018 Interim Results
The first interim results after the Group expanded the core capital with profit and revenue growth After tax profit of [..]
 
More From Health
Over 2025, The Global HPMC Capsules Market [..]
HPMC capsules are strictly non-toxic and qualify to be Kosher and Halal-certified, which is why their popularity has grown in [..]
Indiva åbner vejen til det europæiske cannabismarked [..]
Aftalen omfatter en licens til 100% overtagelse af dyrkning og ekspedition af cannabis til medicinske formål under Lægemiddelstyrelsens udviklingsprogram. [..]
Breathe easy at home with Blueair’s revolutionary [..]
Dubai UAE, November 29, 2018: According to a recent report by the World Health Organisation (WHO) nine in ten people [..]
5 Growth Hacks to Increase Followers on [..]
22 November 2018 – Medium has posted an article in which there is a description of five important tips on [..]
Middle East Organic & Natural Products Expo [..]
The Middle East Organic & Natural Products Expo 2018 is returning to Dubai Convention & Exhibition Centre on November 18-20. [..]

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.